HUE058207T2 - Készítmények és módszerek gonadotropin felszabadító hormon (GNRH) antagonisták elnyújtott idejû felszabadítására - Google Patents

Készítmények és módszerek gonadotropin felszabadító hormon (GNRH) antagonisták elnyújtott idejû felszabadítására

Info

Publication number
HUE058207T2
HUE058207T2 HUE18747581A HUE18747581A HUE058207T2 HU E058207 T2 HUE058207 T2 HU E058207T2 HU E18747581 A HUE18747581 A HU E18747581A HU E18747581 A HUE18747581 A HU E18747581A HU E058207 T2 HUE058207 T2 HU E058207T2
Authority
HU
Hungary
Prior art keywords
ganadotropin
gnrh
antagonists
compositions
methods
Prior art date
Application number
HUE18747581A
Other languages
English (en)
Inventor
Kacker Ravi
S Steiner Mitchell
Original Assignee
Veru Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veru Inc filed Critical Veru Inc
Publication of HUE058207T2 publication Critical patent/HUE058207T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
HUE18747581A 2017-01-31 2018-01-31 Készítmények és módszerek gonadotropin felszabadító hormon (GNRH) antagonisták elnyújtott idejû felszabadítására HUE058207T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762452788P 2017-01-31 2017-01-31

Publications (1)

Publication Number Publication Date
HUE058207T2 true HUE058207T2 (hu) 2022-07-28

Family

ID=62976965

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18747581A HUE058207T2 (hu) 2017-01-31 2018-01-31 Készítmények és módszerek gonadotropin felszabadító hormon (GNRH) antagonisták elnyújtott idejû felszabadítására

Country Status (18)

Country Link
US (2) US20180214507A1 (hu)
EP (2) EP4011386A1 (hu)
JP (1) JP7074963B2 (hu)
KR (1) KR20190110567A (hu)
CN (1) CN110234336A (hu)
AU (1) AU2018217064A1 (hu)
CA (1) CA3052157A1 (hu)
DK (1) DK3576771T3 (hu)
ES (1) ES2914314T3 (hu)
HR (1) HRP20220438T1 (hu)
HU (1) HUE058207T2 (hu)
IL (1) IL268376A (hu)
LT (1) LT3576771T (hu)
MX (2) MX2019009126A (hu)
PL (1) PL3576771T3 (hu)
PT (1) PT3576771T (hu)
UA (1) UA127018C2 (hu)
WO (1) WO2018144603A1 (hu)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11453128B2 (en) 2017-06-29 2022-09-27 Sony Interactive Entertainment Inc. Robot control apparatus, control method and control program
SG11202005949UA (en) 2018-05-24 2020-07-29 Celanese Eva Performance Polymers Corp Implantable device for sustained release of a macromolecular drug compound
US11690807B2 (en) 2018-05-24 2023-07-04 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
CN113226289A (zh) * 2018-10-02 2021-08-06 伊诺科雷技术控股有限公司 人绒毛膜促性腺激素(hcg)的延长释放制剂
CN110681323B (zh) * 2019-08-26 2021-12-21 上海摩漾生物科技有限公司 具有微拓扑结构的高尔夫球型可降解微球及其制备方法
WO2021237039A1 (en) * 2020-05-21 2021-11-25 Veru Inc. Compositions and methods for long term release of gonadotropin-releasing hormone (gnrh) antagonists
CN111728957B (zh) * 2020-07-06 2022-04-19 济南大学 一种托特罗定长效缓释微球及其制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
GB2228262B (en) * 1989-01-25 1992-10-07 Nat Inst Immunology Antigenic derivative of gnrh
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
US6517859B1 (en) 1990-05-16 2003-02-11 Southern Research Institute Microcapsules for administration of neuroactive agents
BR9507313A (pt) 1994-04-08 1997-10-07 Atrix Lab Inc Composição liquida de liberação adequada para a formação de um implante de liberação controlada sistema polimérico curativo filmico microporoso biodegradável precursor de implante de liberação controlada para a implantação em um indivíduo polímero termoplástico solvente orgánico composicão de pré-polimero liquido componente de liberação controlada agente ativo uso da composição liquida de liberação e processos para forma um implante microporoso de liberação prolongada e para liberar um agente ativo em um individuo
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6458387B1 (en) 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
DE10024451A1 (de) * 2000-05-18 2001-11-29 Asta Medica Ag Pharmazeutische Darreichungsform für Peptide, Verfahren zu deren Herstellung und Verwendung
US6805879B2 (en) 2000-06-23 2004-10-19 Biopharm Solutions Inc. Stable polymer aqueous/aqueous emulsion system and uses thereof
ATE303156T1 (de) * 2000-10-30 2005-09-15 Univ Zuerich Verwendung von gnrh-analogue zur behandlung der harninkontinenz
KR100435921B1 (ko) 2000-12-29 2004-06-12 주식회사 태평양 동수역학적 이중 안정화에 의한 안정한 수-유-수 다중에멀젼 시스템 및 이의 제조방법
SI21222A (sl) 2002-05-28 2003-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Postopek za pripravo nanodelcev
EP1382628A1 (en) 2002-07-16 2004-01-21 Polyganics B.V. Biodegradable phase separated segmented/block co-polyesters
AU2003287950B2 (en) * 2002-09-27 2009-01-29 Zentaris Gmbh Administration form for pharmaceutically active peptides with sustained release and method for the production thereof
ES2600554T3 (es) * 2003-07-18 2017-02-09 Oakwood Laboratories L.L.C. Prevención de la reducción del peso molecular del polímero, de la formación de impurezas y de la gelificación en composiciones poliméricas
WO2005067889A1 (en) * 2003-12-30 2005-07-28 Durect Corporation Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh
EP1555278A1 (en) 2004-01-15 2005-07-20 Innocore Technologies B.V. Biodegradable multi-block co-polymers
US7611709B2 (en) 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
EP1835885A1 (en) * 2004-12-23 2007-09-26 Durect Corporation Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of a gnrh
NZ567300A (en) * 2005-10-19 2010-11-26 Kissei Pharmaceutical Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof
RU2427383C2 (ru) * 2006-01-18 2011-08-27 КьюПиЭс, ЭлЭлСи Фармацевтические композиции с повышенной стабильностью
PT103476B (pt) 2006-05-10 2008-09-19 Univ De Coimbra Processo de produção e isolamento de micro- e nanopartículas poliméricas contendo macromoléculas de natureza hidrofílica e termolábil
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
US20090181068A1 (en) * 2008-01-14 2009-07-16 Dunn Richard L Low Viscosity Liquid Polymeric Delivery System
ES2569556T3 (es) * 2008-06-03 2016-05-11 Indivior Uk Limited Complejo de inclusión de hidrogel deshidratado de un agente bioactivo con sistema fluido de administración de medicamento
WO2009155257A1 (en) 2008-06-17 2009-12-23 Indiana University Research And Technology Corporation Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers
KR101113044B1 (ko) * 2008-08-29 2012-02-27 동국제약 주식회사 용매교류증발법에 의한 서방출성 미립구의 제조방법
EP2246063A1 (en) * 2009-04-29 2010-11-03 Ipsen Pharma S.A.S. Sustained release formulations comprising GnRH analogues
TR200907227A2 (tr) 2009-09-18 2011-04-21 Bi̇lgi̇ç Mahmut Çözünürlüğü yüksek stabil mikronize granüller.
US8975270B2 (en) * 2010-06-08 2015-03-10 Rb Pharmaceuticals Limited Injectable flowable composition comprising buprenorphine
EP2859887B1 (en) 2010-07-09 2017-03-22 InnoCore Technologies B.V. Biodegradable phase separated segmented multi block co-polymers and release of biologically active polypeptides
CN102145160A (zh) * 2011-03-07 2011-08-10 深圳市健元医药科技有限公司 一种lhrh拮抗剂注射用的缓释植入制剂
WO2012163519A1 (en) 2011-05-27 2012-12-06 Dutalys Antibodies with improved folding stability
EP2734573B1 (en) 2011-07-22 2021-09-08 InnoCore Technologies Holding B.V. Biodegradable, semi-crystalline, phase separated, thermoplastic multi block copolymers for controlled release of biologically active compounds
CN102488619B (zh) 2011-12-05 2014-08-06 上海交通大学 连续生产艾塞那肽微球的装置及控制微球释放速度的方法
WO2015145353A1 (en) 2014-03-27 2015-10-01 Novartis Ag Spray-dried solid-in-oil-in-water dispersions for inhalation of active pharmaceutical ingredients
US20170290846A1 (en) * 2014-09-30 2017-10-12 University Of Tennessee Research Foundation In situ gelling form for long-acting drug delivery
US20160106804A1 (en) * 2014-10-15 2016-04-21 Yuhua Li Pharmaceutical composition with improved stability

Also Published As

Publication number Publication date
MX2022003967A (es) 2022-04-25
LT3576771T (lt) 2022-04-11
JP2020506232A (ja) 2020-02-27
JP7074963B2 (ja) 2022-05-25
KR20190110567A (ko) 2019-09-30
ES2914314T3 (es) 2022-06-09
CN110234336A (zh) 2019-09-13
EP4011386A1 (en) 2022-06-15
US20180250354A1 (en) 2018-09-06
EP3576771A4 (en) 2020-11-04
HRP20220438T1 (hr) 2022-06-10
UA127018C2 (uk) 2023-03-15
US20180214507A1 (en) 2018-08-02
PL3576771T3 (pl) 2022-08-16
EP3576771B1 (en) 2022-03-09
MX2019009126A (es) 2020-01-20
RU2019123951A (ru) 2021-02-01
CA3052157A1 (en) 2018-08-09
AU2018217064A1 (en) 2019-08-08
IL268376A (en) 2019-09-26
EP3576771A1 (en) 2019-12-11
DK3576771T3 (da) 2022-05-30
RU2019123951A3 (hu) 2021-08-02
WO2018144603A1 (en) 2018-08-09
PT3576771T (pt) 2022-05-30

Similar Documents

Publication Publication Date Title
IL268376A (en) Compositions for long-term release of gonadotropin-releasing hormone (GHRH) inhibitors and methods of their use
IL268895A (en) Compositions and methods for inhibiting proteins with specific binding
GB2582482B (en) CASZ compositions and methods of use
HK1252870A1 (zh) Sirp多肽組合物和使用方法
SG11202100214SA (en) Antagonists of t2r54 and compositions and uses thereof
RS63336B1 (sr) Kompozicije i postupci za isporuku terapijskih agenasa
IL261176B2 (en) Preparations for the controlled release of active ingredients and methods for their preparation
GB2582100B (en) CAS12C Compositions and methods of use
IL268684A (en) Preparations and methods for immuno-oncology
GB2542309B (en) Systems and methods for analyzing the characteristics and compositions of cement additives
ZA201906169B (en) Synthekine compositions and methods of use
HK1251979A1 (zh) 肽組合物和使用方法
HK1254960A1 (zh) 冷沉澱物組合物及其製備方法
IL274524A (en) Preparations and methods for aquaculture
IL275739A (en) Preparations for cryopreservation and methods of their use
PL3539545T3 (pl) Postać krystaliczna antagonisty receptora gnrh i sposób jej wytwarzania
IL262729A (en) Compositions and methods of providing thyroid hormone or analogs thereof
EP3672618A4 (en) COMPOSITIONS AND METHODS OF ADMINISTRATION OF PHARMACOLOGICAL AGENTS
IL251588A0 (en) Methods and preparations for increasing the potency of antifungal agents
KR102388028B9 (ko) 폴리펩타이드 전달용 조성물
SG11202002351SA (en) Poloxamer compositions and methods of making and using same
EP3452077A4 (en) COMPOSITIONS AND METHODS FOR PROVIDING THYROID HORMONE OR THE LIKE THEREOF